CLDX Q3 2024 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+110.3% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$52M-1633.5% margin

Net Income

-$42M-1320.0% margin

EPS (Diluted)

$-0.64

QoQ Revenue Growth

+27.7%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$823M

Total Liabilities

$37M

Stockholders' Equity

$786M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+110.3%
Gross Profit	$3M	$750,000	+325.5%
Operating Income	-$52M	-$41M	-26.4%
Net Income	-$42M	-$38M	-10.1%

Revenue Segments

Grant

$3M100%

Service

$3,0000%